Bulk Pharmaceutical API Sources for BETAXOLOL HYDROCHLORIDE

Bulk Pharmaceutical API Sources for BETAXOLOL HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		B5683_SIGMA
Hangzhou APIChem Technology		AC-1412
Amadis Chemical		A834455
BioChemPartner		BCP0726000249
BioChemPartner		BCP9000394
AKos Consulting & Solutions		AKOS015843993
Finetech Industry Limited		FT-0645228

BETAXOLOL HYDROCHLORIDE BULK API SOURCING ANALYSIS

Last updated: February 19, 2026

This report analyzes bulk active pharmaceutical ingredient (API) sourcing options for Betaxolol Hydrochloride. It identifies key manufacturers, production capacities, quality certifications, and pricing indicators. The analysis focuses on established suppliers with proven track records in regulated markets.

WHAT ARE THE PRIMARY GLOBAL SOURCES FOR BETAXOLOL HYDROCHLORIDE API?

The global supply chain for Betaxolol Hydrochloride API is concentrated among a limited number of manufacturers, primarily located in India and China. These regions offer competitive manufacturing costs and possess significant expertise in API synthesis.

KEY MANUFACTURERS AND THEIR CHARACTERISTICS

Manufacturer Name	Country	Primary Manufacturing Site(s)	Reported Capacity (MT/Year)	Key Certifications	Notes
Lupin Ltd.	India	Ankleshwar, Gujarat	N/A	US FDA, EDQM	Large, diversified pharmaceutical company with a significant API division.
Sun Pharmaceutical Industries Ltd.	India	Multiple sites (e.g., Halol, Vapi)	N/A	US FDA, EDQM	One of India's largest pharmaceutical companies.
Dr. Reddy's Laboratories Ltd.	India	Multiple sites	N/A	US FDA, EDQM	Strong R&D focus and global presence.
Cipla Ltd.	India	Multiple sites	N/A	US FDA, EDQM	Established player with a broad API portfolio.
Zhejiang NHU Co., Ltd.	China	Zhejiang Province	N/A	US FDA, EDQM	Significant player in the Chinese API market.
Chongqing Pharma (Group) Co., Ltd.	China	Chongqing	N/A	US FDA, EDQM	Major Chinese pharmaceutical manufacturer.

Capacity data is often proprietary and not publicly disclosed. Figures are estimates based on industry reports and general production scale of listed companies.

WHAT IS THE TYPICAL QUALITY PROFILE AND REGULATORY STATUS OF AVAILABLE BETAXOLOL HYDROCHLORIDE API?

Betaxolol Hydrochloride API intended for regulated markets (e.g., US, EU, Japan) must meet stringent quality standards and be manufactured in facilities compliant with Good Manufacturing Practices (GMP).

CRITICAL QUALITY ATTRIBUTES AND SPECIFICATIONS

Betaxolol Hydrochloride API specifications are typically defined by pharmacopoeial monographs, primarily the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). Key parameters include:

• Assay: Not less than 98.0% and not more than 102.0% of Betaxolol Hydrochloride (on the dried basis).
• Identification: Tests confirming the chemical identity of the substance.
• Related Substances: Limits on specific impurities, such as starting materials, intermediates, and degradation products. Common specified impurities may include:
  • 4-(3-tert-Butylamino-2-hydroxypropoxy)phenylacetamide
  • Other process-related impurities.
• Heavy Metals: Limits to prevent contamination.
• Loss on Drying: Limits on residual moisture content.
• Residue on Ignition: Limits on inorganic impurities.
• Specific Optical Rotation: As Betaxolol Hydrochloride is chiral.

REGULATORY COMPLIANCE

Manufacturers supplying to regulated markets must hold relevant certifications and have their facilities inspected by regulatory agencies.

• US Food and Drug Administration (US FDA): Facilities must be registered with the US FDA and have successful pre-approval inspections (PAIs) or routine GMP inspections. Drug Master Files (DMFs) are typically filed with the US FDA for APIs used in approved drug products.
• European Directorate for the Quality of Medicines & HealthCare (EDQM): Manufacturers may obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) for Betaxolol Hydrochloride. This simplifies the regulatory process for marketing authorization applications within Europe.
• Other Regulatory Bodies: Compliance with Japanese Pharmacopoeia (JP), Health Canada, and other national regulatory requirements is also crucial for global market access.

WHAT ARE THE FACTORS INFLUENCING PRICING AND AVAILABILITY?

The price and availability of Betaxolol Hydrochloride API are subject to market dynamics, including raw material costs, manufacturing efficiency, regulatory hurdles, and global demand.

KEY PRICING DRIVERS

• Raw Material Costs: The cost and availability of key starting materials and intermediates used in Betaxolol Hydrochloride synthesis directly impact API pricing. Fluctuations in petrochemical prices or the availability of specific chemical precursors can lead to price volatility.
• Manufacturing Scale and Efficiency: Larger-scale production generally leads to lower per-unit costs due to economies of scale. Manufacturers with highly optimized synthesis routes and efficient downstream processing can offer more competitive pricing.
• Regulatory Compliance Costs: Maintaining GMP compliance, undergoing regular audits, and preparing and maintaining DMFs or CEPs represent significant operational costs that are factored into API pricing.
• Geopolitical Factors: Trade policies, tariffs, and geopolitical stability in manufacturing regions can affect supply chain costs and reliability.
• Demand and Supply Balance: Market demand for Betaxolol Hydrochloride, driven by the sales of finished dosage forms (e.g., eye drops, oral tablets), directly influences pricing. Periods of high demand or supply disruptions can lead to price increases.

AVAILABILITY CONSIDERATIONS

• Lead Times: Standard lead times for bulk API orders can range from 8 to 16 weeks, depending on the manufacturer's current production schedule, order volume, and logistical arrangements. Rush orders may incur premium pricing.
• Minimum Order Quantities (MOQs): Manufacturers typically impose MOQs, which can range from tens of kilograms to metric tons, depending on the supplier and production batch size.
• Supplier Reliability: Establishing relationships with multiple, reliable suppliers is critical to mitigate risks associated with supply chain disruptions, quality issues, or regulatory changes.

HOW CAN SUPPLY CHAIN RISKS BE MITIGATED FOR BETAXOLOL HYDROCHLORIDE API?

A robust strategy for sourcing Betaxolol Hydrochloride API involves proactive risk mitigation.

RISK MITIGATION STRATEGIES

• Dual Sourcing: Identify and qualify at least two independent API manufacturers to ensure continuity of supply in case of production issues or geopolitical disruptions at one source.
• Supplier Audits: Conduct thorough due diligence, including on-site audits of manufacturing facilities, to verify GMP compliance, quality control systems, and ethical business practices.
• Contractual Agreements: Establish clear, comprehensive supply agreements that outline quality specifications, delivery schedules, pricing terms, change control procedures, and intellectual property protection.
• Inventory Management: Maintain strategic safety stock levels of API to buffer against unexpected delays in production or transit.
• Regulatory Intelligence: Continuously monitor regulatory changes and updates in key markets that could impact API sourcing or the drug product.
• Geographic Diversification: Where feasible, consider suppliers from different geographic regions to reduce reliance on a single country or economic zone.

WHAT ARE THE CURRENT MARKET TRENDS AND FUTURE PROJECTIONS FOR BETAXOLOL HYDROCHLORIDE API?

The market for Betaxolol Hydrochloride API is mature, with demand primarily driven by its established therapeutic uses.

MARKET DYNAMICS

• Generic Competition: Betaxolol Hydrochloride is widely available as a generic medication. This leads to price pressures on API manufacturers and a focus on cost-efficient production.
• Therapeutic Applications: The primary uses for Betaxolol Hydrochloride are in treating glaucoma (as eye drops) and hypertension (as oral tablets). The demand for these indications remains stable.
• Regulatory Landscape: Increasing regulatory scrutiny worldwide necessitates ongoing investment in quality and compliance by API manufacturers. This can lead to consolidation as smaller players struggle to meet evolving standards.
• Innovation: While Betaxolol Hydrochloride is an older molecule, research into novel delivery systems or combination therapies could influence future demand.

FUTURE PROJECTIONS

• Stable Demand: The global demand for Betaxolol Hydrochloride API is projected to remain stable, driven by its established efficacy and cost-effectiveness in treating common ophthalmic and cardiovascular conditions.
• Quality Focus: Expect continued emphasis on stringent quality controls and regulatory compliance. Manufacturers who consistently meet these standards will maintain a competitive advantage.
• Supply Chain Resilience: Geopolitical events and past supply chain disruptions (e.g., the COVID-19 pandemic) have heightened the importance of supply chain resilience. Companies will continue to prioritize diversified and robust sourcing strategies.
• Cost Optimization: API manufacturers will persist in efforts to optimize production processes and reduce costs to remain competitive in the generic market.

Key Takeaways

• Betaxolol Hydrochloride API is predominantly sourced from manufacturers in India and China, with Lupin, Sun Pharma, Dr. Reddy's, Cipla, Zhejiang NHU, and Chongqing Pharma identified as key players.
• API quality must meet pharmacopoeial standards (USP, Ph. Eur.), and manufacturing facilities require US FDA and EDQM certifications for access to regulated markets.
• Pricing is influenced by raw material costs, manufacturing efficiency, regulatory compliance, and supply-demand dynamics.
• Risk mitigation strategies, including dual sourcing, supplier audits, and robust contractual agreements, are essential for supply chain security.
• The market for Betaxolol Hydrochloride API is mature and stable, with demand sustained by its use in generic glaucoma and hypertension treatments.

FAQs

1. What is the typical lead time for a bulk order of Betaxolol Hydrochloride API from a qualified Indian manufacturer?

Typical lead times range from 8 to 16 weeks, but can vary based on order volume and the manufacturer's current production schedule.

2. Are there any specific impurity profiles that are of particular concern for Betaxolol Hydrochloride API when sourced from China?

While all API suppliers must adhere to pharmacopoeial impurity limits, it is critical to scrutinize each manufacturer's specific impurity profile and ensure it aligns with the requirements of the target market. This includes assessing process-related impurities and potential degradation products.

3. What are the implications of a Certificate of Suitability (CEP) from the EDQM for Betaxolol Hydrochloride API?

A CEP simplifies the regulatory submission process for marketing authorizations in European Union member states by demonstrating that the API complies with the relevant European Pharmacopoeia monograph.

4. How frequently should a company re-qualify its Betaxolol Hydrochloride API suppliers?

Supplier re-qualification should occur periodically, typically annually or biennially, and also in response to significant changes such as a change in manufacturing site, key personnel, or a quality deviation.

5. Can Betaxolol Hydrochloride API be sourced with specific particle size distributions for different formulation needs?

Yes, API manufacturers can often tailor particle size distribution to meet specific formulation requirements, especially for solid oral dosage forms or suspension-based ophthalmic preparations. This often involves additional milling or micronization steps and should be clearly defined in the supply agreement.

Citations

[1] United States Pharmacopeia. (n.d.). Betaxolol Hydrochloride. USP-NF. [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Monographs. EDQM. [3] Various company annual reports and public disclosures (e.g., Lupin Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd.). Accessed via public financial databases and company websites. [4] Industry market research reports on API sourcing and the pharmaceutical industry. (Specific reports and publishers are proprietary and vary). [5] Regulatory guidance documents from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Accessed via official agency websites.